肿瘤指南

订阅

MedSci主页 / 所有栏目 / 肿瘤指南

乳腺癌诊疗指南（2022年版）

2022-04-11 中华人民共和国国家卫生健康委员会 中华人民共和国国家卫生健康委员会官网

国家卫健委乳腺癌诊疗指南

为进一步规范我国乳腺癌诊疗行为，提高医疗机构乳腺癌诊疗水平，改善乳腺癌患者预后，保障医疗质量和医疗安全，特制定本指南。

中文标题：

乳腺癌诊疗指南（2022年版）

发布机构：

中华人民共和国国家卫生健康委员会

发布日期：

2022-04-11

简要介绍：

乳腺癌是女性常见的恶性肿瘤之一，发病率位居女性恶性肿瘤的首位，严重危害妇女的身心健康。目前，通过采用综合治疗手段，乳腺癌已成为疗效最佳的实体肿瘤之一。为进一步规范我国乳腺癌诊疗行为，提高医疗机构乳腺癌诊疗水平，改善乳腺癌患者预后，保障医疗质量和医疗安全，特制定本指南。

相关资料下载：
[AttachmentFileName(sort=1, fileName=乳腺癌诊疗指南+（2022年版）.pdf)] GetToolGuiderByIdResponse(projectId=1, id=2d53a1c00250989b, title=乳腺癌诊疗指南（2022年版）, enTitle=, guiderFrom=中华人民共和国国家卫生健康委员会官网, authorId=0, author=, summary=为进一步规范我国乳腺癌诊疗行为，提高医疗机构乳腺癌诊疗水平，改善乳腺癌患者预后，保障医疗质量和医疗安全，特制定本指南。, cover=https://img.medsci.cn/Random/diagnostic-form-in-hospital-conceptual-image-7JAH3GT.jpg, journalId=0, articlesId=null, associationId=1653, associationName=中华人民共和国国家卫生健康委员会, associationIntro=, copyright=0, guiderPublishedTime=Mon Apr 11 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">乳腺癌是女性常见的恶性肿瘤之一，发病率位居女性恶性肿瘤的首位，严重危害妇女的身心健康。目前，通过采用综合治疗手段，乳腺癌已成为疗效最佳的实体肿瘤之一。为进一步规范我国乳腺癌诊疗行为，提高医疗机构乳腺癌诊疗水平，改善乳腺癌患者预后，保障医疗质量和医疗安全，特制定本指南。</span></p>, tagList=[TagDto(tagId=72213, tagName=国家卫健委), TagDto(tagId=440210, tagName=乳腺癌诊疗指南)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=89, categoryName=乳腺癌, tenant=100), CategoryDto(categoryId=21054, categoryName=梅斯医学-乳腺癌网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=285, articleKeyword=乳腺癌, articleKeywordNum=6, guiderKeywordId=308, guiderKeyword=诊疗指南, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=19573, appHits=702, showAppHits=0, pcHits=2673, showPcHits=18870, likes=0, shares=95, comments=4, approvalStatus=1, publishedTime=Tue Jul 12 20:35:00 CST 2022, publishedTimeString=2022-04-11, pcVisible=1, appVisible=1, editorId=0, editor=lixiang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=7, createdBy=null, createdName=lixiang, createdTime=Thu Jul 07 17:06:42 CST 2022, updatedBy=6459136, updatedName=艺玮, updatedTime=Sat Jan 06 18:43:22 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=乳腺癌诊疗指南+（2022年版）.pdf)])
乳腺癌诊疗指南+（2022年版）.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2226357, encodeId=0571222635e23, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=655b8245725, createdName=ms6000000190242997, createdTime=Wed Sep 18 11:06:35 CST 2024, time=2024-09-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1232906, encodeId=c7cb12329062d, content=好好学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150928/IMG5608CD12CF3009910.jpg, createdBy=2e761652994, createdName=海上飘星, createdTime=Sun Jul 17 08:00:15 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232563, encodeId=94101232563f9, content=下载来学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220718/40f20a20ac39449bb9b54f0a56b3bd59/badab63a8f8940b1aa22f908b6cb9dc4.jpg, createdBy=5b9f6414712, createdName=ms5000000275821148, createdTime=Fri Jul 15 06:01:14 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232078, encodeId=d5f712320e86b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60445479842, createdName=ms2000000529313829, createdTime=Tue Jul 12 20:48:48 CST 2022, time=2022-07-12, status=1, ipAttribution=)]
    2024-09-18 ms6000000190242997 来自湖北省

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2226357, encodeId=0571222635e23, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=655b8245725, createdName=ms6000000190242997, createdTime=Wed Sep 18 11:06:35 CST 2024, time=2024-09-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1232906, encodeId=c7cb12329062d, content=好好学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150928/IMG5608CD12CF3009910.jpg, createdBy=2e761652994, createdName=海上飘星, createdTime=Sun Jul 17 08:00:15 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232563, encodeId=94101232563f9, content=下载来学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220718/40f20a20ac39449bb9b54f0a56b3bd59/badab63a8f8940b1aa22f908b6cb9dc4.jpg, createdBy=5b9f6414712, createdName=ms5000000275821148, createdTime=Fri Jul 15 06:01:14 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232078, encodeId=d5f712320e86b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60445479842, createdName=ms2000000529313829, createdTime=Tue Jul 12 20:48:48 CST 2022, time=2022-07-12, status=1, ipAttribution=)]
    2022-07-17 海上飘星

    好好学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2226357, encodeId=0571222635e23, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=655b8245725, createdName=ms6000000190242997, createdTime=Wed Sep 18 11:06:35 CST 2024, time=2024-09-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1232906, encodeId=c7cb12329062d, content=好好学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150928/IMG5608CD12CF3009910.jpg, createdBy=2e761652994, createdName=海上飘星, createdTime=Sun Jul 17 08:00:15 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232563, encodeId=94101232563f9, content=下载来学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220718/40f20a20ac39449bb9b54f0a56b3bd59/badab63a8f8940b1aa22f908b6cb9dc4.jpg, createdBy=5b9f6414712, createdName=ms5000000275821148, createdTime=Fri Jul 15 06:01:14 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232078, encodeId=d5f712320e86b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60445479842, createdName=ms2000000529313829, createdTime=Tue Jul 12 20:48:48 CST 2022, time=2022-07-12, status=1, ipAttribution=)]
    2022-07-15 ms5000000275821148

    下载来学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2226357, encodeId=0571222635e23, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=655b8245725, createdName=ms6000000190242997, createdTime=Wed Sep 18 11:06:35 CST 2024, time=2024-09-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1232906, encodeId=c7cb12329062d, content=好好学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150928/IMG5608CD12CF3009910.jpg, createdBy=2e761652994, createdName=海上飘星, createdTime=Sun Jul 17 08:00:15 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232563, encodeId=94101232563f9, content=下载来学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220718/40f20a20ac39449bb9b54f0a56b3bd59/badab63a8f8940b1aa22f908b6cb9dc4.jpg, createdBy=5b9f6414712, createdName=ms5000000275821148, createdTime=Fri Jul 15 06:01:14 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232078, encodeId=d5f712320e86b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60445479842, createdName=ms2000000529313829, createdTime=Tue Jul 12 20:48:48 CST 2022, time=2022-07-12, status=1, ipAttribution=)]
    2022-07-12 ms2000000529313829

    学习

    0

拓展阅读

JAMA Oncol：乳腺癌外科预防策略中终身患病风险阈值的界定

本研究首创性地结合临床循证与经济评估，细化并科学定义了乳腺癌风险降低乳房切除术的终身风险阈值，修正了当前国际及英国指南中传统30%阈值的笼统认知，为临床决策提供理性量化依据。

【综述】｜乳腺癌术后孤立腋窝淋巴结复发的临床特征与治疗进展

本综述全面梳理AR的临床特征、高危因素及个体化管理策略，重点探讨不同腋窝手术方式、放疗与系统治疗对AR风险的影响。此外，未来亟待开展更多高质量临床研究，进一步明确AR的预后因素，优化个体化治疗方案。

Front Public Health：夜间光照与乳腺癌风险关联研究，基于21项观察性研究的荟萃分析

该研究证实 LAN 暴露与乳腺癌风险增加相关，尤其在亚洲人群中更为突出。

导管原位癌患者个体化治疗依据：BMJ揭示8年随访不同风险组浸润癌发生率与生存差异

该项研究填补了DCIS患者未接受初期手术治疗的长期自然病程证据空白。

从“等进展”到“抢进展”，梁旭教授谈乳腺癌治疗进入“快进”模式

【医悦汇】特邀北京大学肿瘤医院梁旭教授做客“对话大咖”栏目，分享激素受体阳性（HR+）/HER2-晚期乳腺癌研究进展及面临的挑战！

JAMA子刊：乳腺癌患者放射治疗与降低阿尔茨海默病风险相关，而化疗及内分泌治疗则无显著影响

本研究评估了乳腺癌幸存者与AD发病风险的关系及其与不同治疗方式的潜在联系。

2022 BAD/BPG指南：窄谱中波紫外线光疗

英国皮肤科医师协会(BAD,British Association of Dermatologists) · 2022-05-23

2020 ECCO/ESPGHAN指南：儿童克罗恩病的药物治疗

欧洲克罗恩病和结肠炎组织(ECCO,European Cron&#039;s and Colitis Organisation) · 2020-10-07

中国乳腺癌筛查与早期诊断指南

中国抗癌协会乳腺癌专业委员会(CACA-CBCS,Chinese Anti-Cancer Association, Committee of Breast Cancer Society) · 2022-04-28

2020 AAO指南：成人眼科综合评估

美国眼科学会(AAO,American Academy of Ophthalmology) · 2020-11-30

疟疾诊疗指南

浙江大学医学院附属第一医院 · 2022-07-29

ESC和ACC/AHA/HFSA心力衰竭指南的建议之间的头对头比较

欧洲心脏病学会(ESC,European Society of Cardiology) · 2022-08-25